Brief: Trevena Presents Phase 1 Data On TRV250 For Acute Migraine At American College Of Neuropsychopharmacology 2019 Annual Meeting
12/12/2019 13:06
Dec 12 (Reuters) - Trevena Inc TRVN.O :
* TREVENA PRESENTS PHASE 1 DATA ON TRV250 FOR ACUTE MIGRAINE
AT
AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY 2019 ANNUAL MEETING
Source text for Eikon: ID:nGNX3jDBH6
Further company coverage: TRVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevena
See all newsTrevena Inc reports results for the quarter ended in June - Earnings Summary
Trevena Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Trevena Q2 EPS USD -0.23
Brief: Trevena Announces $2M Non-Dilutive Financing Tranche And Reduction In Outstanding Liabilities In Connection With Existing Ex-Us Royalty Financing
U.S. STOCKS ON THE MOVE-Allstate, MicroStrategy, AutoZone